Haleon plc (NYSE:HLN) Receives Consensus Recommendation of “Hold” from Analysts

Haleon plc (NYSE:HLN) has been assigned a consensus recommendation of “Hold” from the eight analysts that are covering the company, Marketbeat.com reports. Six investment analysts have rated the stock with a hold recommendation, one has given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $10.95.

HLN has been the subject of a number of recent research reports. Hsbc Global Res downgraded Haleon from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, March 5th. HSBC reaffirmed a “hold” rating on shares of Haleon in a research note on Wednesday, March 5th. Sanford C. Bernstein cut shares of Haleon from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 8th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Haleon in a research report on Monday, March 3rd. Finally, Morgan Stanley lowered Haleon from an “overweight” rating to an “equal weight” rating in a research report on Friday, January 10th.

Haleon Stock Performance

NYSE:HLN opened at $10.16 on Thursday. The company has a market cap of $46.00 billion, a P/E ratio of 29.88, a P/E/G ratio of 2.82 and a beta of 0.25. Haleon has a twelve month low of $7.99 and a twelve month high of $10.80. The company’s 50-day moving average price is $10.00 and its 200-day moving average price is $9.87. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44.

Haleon (NYSE:HLN) last issued its earnings results on Thursday, February 27th. The company reported $0.05 earnings per share for the quarter. Haleon had a return on equity of 14.76% and a net margin of 10.85%. The business had revenue of $3.54 billion for the quarter, compared to analysts’ expectations of $3.38 billion. On average, sell-side analysts forecast that Haleon will post 0.43 earnings per share for the current fiscal year.

Haleon Increases Dividend

The business also recently announced a — dividend, which will be paid on Thursday, June 5th. Investors of record on Friday, April 25th will be issued a $0.1166 dividend. This represents a yield of 1.6%. The ex-dividend date of this dividend is Friday, April 25th. This is an increase from Haleon’s previous — dividend of $0.05. Haleon’s dividend payout ratio (DPR) is 58.97%.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. Wellington Management Group LLP lifted its stake in Haleon by 67.5% during the 4th quarter. Wellington Management Group LLP now owns 15,328,325 shares of the company’s stock worth $146,232,000 after acquiring an additional 6,175,835 shares in the last quarter. FMR LLC lifted its position in shares of Haleon by 5.8% during the third quarter. FMR LLC now owns 104,918,269 shares of the company’s stock worth $1,110,035,000 after purchasing an additional 5,768,117 shares in the last quarter. Point72 Asset Management L.P. purchased a new position in shares of Haleon in the fourth quarter valued at approximately $45,110,000. Raymond James Financial Inc. acquired a new position in shares of Haleon in the fourth quarter valued at approximately $42,193,000. Finally, Bank Julius Baer & Co. Ltd Zurich purchased a new stake in Haleon during the 4th quarter worth approximately $39,628,000. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.